Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.
about
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaProbiotics for preventing ventilator-associated pneumoniaInterventions to improve professional adherence to guidelines for prevention of device-related infectionsProbiotics for preventing ventilator-associated pneumoniaInterventions aimed at improving professional adherence to guidelines for prevention of device-related infectionsEpidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubsNosocomial bloodstream infection and clinical sepsisOpinion: the clinical use of selective digestive decontaminationOptimizing antibiotic therapy in the intensive care unit setting.Cost effectiveness in treating ventilator-associated pneumoniaIncidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective studyVentilator associated pneumonia: comparison between quantitative and qualitative cultures of tracheal aspiratesCosts and risk factors for ventilator-associated pneumonia in a Turkish university hospital's intensive care unit: a case-control studyBench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumoniaIntensive care unit-acquired urinary tract infections in a regional critical care systemThe Host's Reply to Candida BiofilmTwo-dimensionality of yeast colony expansion accompanied by pattern formationStructural evidence suggests that antiactivator ExsD from Pseudomonas aeruginosa is a DNA binding proteinCrystal structure and oligomeric state of the RetS signaling kinase sensory domainThe Transcription Factor AmrZ Utilizes Multiple DNA Binding Modes to Recognize Activator and Repressor Sequences of Pseudomonas aeruginosa Virulence GenesCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaC5a mediates peripheral blood neutrophil dysfunction in critically ill patientsAntimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999Acyclic N-halamine-immobilized polyurethane: Preparation and antimicrobial and biofilm-controlling functionsAn N-halamine-based rechargeable antimicrobial and biofilm controlling polyurethaneThe galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung.ChIP-Seq and RNA-Seq reveal an AmrZ-mediated mechanism for cyclic di-GMP synthesis and biofilm development by Pseudomonas aeruginosaMultiple FadD acyl-CoA synthetases contribute to differential fatty acid degradation and virulence in Pseudomonas aeruginosaPtrB of Pseudomonas aeruginosa suppresses the type III secretion system under the stress of DNA damage.AmrZ modulates Pseudomonas aeruginosa biofilm architecture by directly repressing transcription of the psl operonGram-Positive Uropathogens, Polymicrobial Urinary Tract Infection, and the Emerging Microbiota of the Urinary TractVentilator-associated pneumonia: diagnosis, treatment, and preventionFunctional domains of ExsA, the transcriptional activator of the Pseudomonas aeruginosa type III secretion systemCharacterization of ExsA and of ExsA-dependent promoters required for expression of the Pseudomonas aeruginosa type III secretion system.Cdc24, the GDP-GTP exchange factor for Cdc42, is required for invasive hyphal growth of Candida albicans.Solution structure and properties of AlgH from Pseudomonas aeruginosa.Oral vaccination of BALB/c mice with Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model.Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant.Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccineFructose-enhanced reduction of bacterial growth on nanorough surfaces.
P2860
Q22241905-DCCDC01A-1C6F-4936-B38D-606611F4084DQ24193079-0369B745-4268-4176-8A84-96DFB5A46A67Q24199084-426AAF99-AEE5-4278-8EF5-C996D84F532EQ24235329-D16F128A-B719-4E63-8998-0901D39415DBQ24245725-51F941AA-F789-4535-81C2-84BB5872694FQ24562996-ECE5AE43-E3D9-4956-ADA4-B71A80ED81B9Q24600365-BDD690E3-C716-409F-A400-C6A943E5BF6BQ24795736-C3A63359-8AA1-4EDD-98ED-5A6BD426CB12Q24796204-38EBEDA9-3481-4A9C-9DEF-91DD431EAE20Q24796271-D88E733F-F63E-41EA-9F89-81672835C4ACQ24798675-7C085DEA-54E3-4DDF-AB3A-D52D959E4AAAQ24801258-6E33720C-4BE8-4C13-A810-FE019F5B5A0EQ24803442-3CD542D2-E47D-4751-A0E5-F1817500D900Q24811492-B76A7909-328A-44BB-BDA1-F1D7447508B6Q24811998-C662E460-1000-4BEE-92D8-6109D7A45D7BQ26752938-6F0452CD-C5D4-4B27-98ED-47826A5EE9A3Q27320135-2C3C68E8-6F7B-46E6-8808-C53BFD24A204Q27653885-95B8E39D-ECD8-4831-B4DE-0ECB04C1895EQ27659268-BFD3AEE3-761B-4080-AB50-FAE75EC6E4B2Q27678592-79F51358-229C-454E-A020-424C0269276DQ28085517-2A6C2F3E-2A63-43FE-A3B6-3C4B013F2533Q28239494-40269B0D-900B-49D8-93B1-F6966DCE6C92Q28366760-BF843787-7D20-44A8-AF24-57A18966A041Q28396548-A1ACA67F-BA2D-406B-84DF-DE3A41D4C834Q28397054-FCAC1EB2-584E-4256-8E19-777B9F6CAAFAQ28492530-D96F845F-2795-4B1C-B67C-989E81C859D7Q28492571-C625F67F-A2B5-422F-8769-C5B3906F11D0Q28492660-4D9A1DA6-69EC-49E6-9427-429ED931CFE3Q28492989-FEF4A586-89E0-4197-B156-011616A8C01EQ28493163-7C4ECDEF-3E9A-432A-BBC6-AEA74ABCC6FCQ28829569-68B53430-8B2D-481C-8313-7352098E1C7FQ29012676-834A56DA-EB83-419F-A1AE-E2C472C9067FQ29346800-2043F32E-68B3-4F79-8288-530AA556355AQ29346817-E9BAA274-0BEC-4E7B-B4F2-08300614CCE6Q30164900-B6D8F53D-FBC1-4CF0-98E2-DA75826D343FQ30373528-F279E73F-4BBF-415B-B962-061A04AB2078Q30435195-00A2A671-4091-4F5A-8B24-5AC2408F9F0BQ30453151-DF6C05DE-165D-4111-B408-DE9FBB8C7EFBQ30453226-E77B03B5-AF14-47D5-9E5D-D99352AEA995Q30470545-B83FEA6A-0553-4110-AB7C-3AA8BD0F84ED
P2860
Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Nosocomial infections in medic ...... nfections Surveillance System.
@en
Nosocomial infections in medic ...... nfections Surveillance System.
@nl
type
label
Nosocomial infections in medic ...... nfections Surveillance System.
@en
Nosocomial infections in medic ...... nfections Surveillance System.
@nl
prefLabel
Nosocomial infections in medic ...... nfections Surveillance System.
@en
Nosocomial infections in medic ...... nfections Surveillance System.
@nl
P2093
P1476
Nosocomial infections in medic ...... nfections Surveillance System.
@en
P2093
Edwards JR
Richards MJ
P304
P356
10.1097/00003246-199905000-00020
P407
P577
1999-05-01T00:00:00Z